RESEARCH NOTE

Anti-HCV Prevalence and Risk Factors Analysis in Pregnant Women in Central Brazil

Regina MB Martins, Bart OM Vanderborght*, Caroline Rouzere*, Divina DP Cardoso, Marli SP Azevedo, Clara FT Yoshida**

Departamento de Microbiologia, IPTESP, Universidade Federal de Goiás, Caixa Postal 131, 74605-900 Goiânia, GO, Brasil *Inunogenetics N.V., Ghent, Belgium **Departamento de Virologia, Instituto Oswaldo Cruz, Av. Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brasil

Key words: hepatitis C virus - anti-HCV - pregnant women


Data concerning anti-HCV prevalence in Brazil are still rare (BOM Vanderborght et al. 1993 Vox Sang 65: 122-125). A recent study in 2,250 male blood donors from Goiânia, Central Brazil, revealed an anti-HCV prevalence of 1.4%, after confirmation by line immunoassay (Inno-LIA HCV Ab II, Innogenetics, Belgium) (RMB Martins, unpublished data).

This study was undertaken to determine the anti-HCV prevalence in pregnant women in Central Brazil and to study possible risk factors associated with seropositivity. Samples from 1,273 pregnant women averaging 25 years of age (range: 12-58 years), were collected at the Child-Maternal Hospital in Goiânia from July 1990 to December 1992.

Data concerning the possible HCV parenteral infection route and sexual risk behavior was obtained by means of a questionnaire. Sera were stored at -20°C until tested. For screening purposes, a second-generation ELISA was used, which included core, NS3 and NS5 recombinant antigens of HCV (CFT Yoshida et al. 1993 Rev Inst Med trop S Paulo 35: 315-321). Positive sera were retested for confirmation using two assays: Inno-LIA II (NS4, NS5 and core antigens) and Inno-LIA III (core, E2/NS1, NS3, NS4 and NS5 antigens; Innogenetics). The chi-square test with Yates’ correction was used for statistical analysis.

Twenty two (1.7%) sera reacted positively in the screening assay; twelve (0.9%) were confirmed positive by Inno-LIA II and III tests. Antibodies against core, E2/NS1, NS3, NS4, and NS5 antigens of HCV were detected respectively in 91.6%, 41.6%, 75.5%, 58.3%, and 41.6% of the positive samples. All results obtained with the Inno-LIA II were confirmed by Inno-LIA III.

Anti-HCV prevalence rose with increasing age among pregnant women who were less than 21 years old (0.2%) and in those who were 21-30 years old (1.2%) (p<0.05), and then decreased in older women (p>0.05). Among all risk factors studied, previous blood transfusion (p<0.001), intravenous drug use (p<0.001) and tattoos (p<0.01) were statistically associated with seropositivity in 1,243 pregnant women. Two women who were anti-HCV positive did not answer the questionnaire (Table).

Using second and third generation tests, the anti-HCV prevalence is 0.9% in Central Brazilian pregnant women and it is similar to those found in French (F Roudot-Thoraval et al. 1992 Gastroenterol Clin Biol 16: 255-259) and in healthy pregnant Taiwanese women (HH Lin et al. 1993 Vox Sang 65: 117-121). These results show that the anti-HCV prevalence rate in pregnant women is slightly lower but not statistically different from that found in male blood donors (1.4%), and that parenteral transmission seems to be the major route of HCV infection in Central Brazil.

Additional studies of babies born to infected mothers should be carried to evaluate the HCV vertical transmission in Brazil.

**Table**

<table>
<thead>
<tr>
<th>Risk factors (frequency %)</th>
<th>Anti-HCV % (No. pos./No. tested)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood transfusion (9.9)</td>
<td>Factor present Factor absent</td>
</tr>
<tr>
<td>IV Drug use (1.6)</td>
<td>4.0 (5/123) 0.4 (5/120)*</td>
</tr>
<tr>
<td>Tattoo (4.9)</td>
<td>28.5 (27/97) 1.9 (8/420)*</td>
</tr>
<tr>
<td>Household contact (10.1)</td>
<td>4.9 (3/61) 0.6 (7/1182)*</td>
</tr>
<tr>
<td>Multiple partners (9.2)</td>
<td>0.8 (1/126) 0.8 (9/1117)</td>
</tr>
<tr>
<td>STD (4.1)</td>
<td>1.9 (1/51) 0.7 (9/1922)</td>
</tr>
</tbody>
</table>

* : p<0.001; **: p<0.01

Acknowledgements: to Research Foundation for Microbial Disease of Osaka University, Japan for supplying the HCV recombinant antigens. To F Shapiro for reviewing the manuscript; to TT Sousa, DAO Queiroz and AMB Tavares for the collection of sera, and to EJ Souza for technical assistance.

Received 6 July 1994
Accepted 28 November 1994